Actualités Melinta Therapeutics Inc - MLNT | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase

MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a...

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals

Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core...

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company

MORRISTOWN, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”...

Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures

Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured...

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company”...

Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019

MORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Tr...

~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Melinta Therapeutics Inc (MLNT)

Outils de qualité professionnelle, pour des investisseurs individuels.

MLNT Actualités

Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company

Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

Current Report Filing (8-k)

Current Report Filing (8-k)

Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019

Quarterly Report (10-q)

Current Report Filing (8-k)

Initial Statement of Beneficial Ownership (3)

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Tr...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Melinta Therapeutics Inc (MLNT) Actualités

Melinta Therapeutics Inc (MLNT)

Outils de qualité professionnelle, pour des investisseurs individuels.

MLNT Actualités

Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company

Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

Current Report Filing (8-k)

Current Report Filing (8-k)

Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019

Quarterly Report (10-q)

Current Report Filing (8-k)

Initial Statement of Beneficial Ownership (3)

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Tr...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres